Federal Register of Legislation - Australian Government

Primary content

SR 1990 No. 343 Regulations as made
Principal Regulations; Repeals the Health Insurance (Variation of Pathology Services Table) (No. 2) Regulations.
Tabling HistoryDate
Tabled HR07-Nov-1990
Tabled Senate07-Nov-1990
Gazetted 31 Oct 1990
Date of repeal 01 Dec 1991
Repealed by Repealed by Health Insurance (1991-1992) Pathology Services Table (SR 1991 No. 353).

1990 No. 343*1* HEALTH INSURANCE (1990-91 PATHOLOGY SERVICES TABLE)
REGULATIONS

*1* Notified in the Commonwealth of Australia Gazette on 31 October 1990.

1990 No. 343 HEALTH INSURANCE (1990-91 PATHOLOGY SERVICES TABLE) REGULATIONS
- REG 1
Citation

1. These Regulations may be cited as the Health Insurance (1990-91 Pathology Services Table) Regulations.

1990 No. 343 HEALTH INSURANCE (1990-91 PATHOLOGY SERVICES TABLE) REGULATIONS
- REG 2
Commencement

2. These Regulations commence on 1 November 1990.

1990 No. 343 HEALTH INSURANCE (1990-91 PATHOLOGY SERVICES TABLE) REGULATIONS
- REG 3
Repeal

3. Statutory Rules 1990 No. 312 are repealed.

1990 No. 343 HEALTH INSURANCE (1990-91 PATHOLOGY SERVICES TABLE) REGULATIONS
- REG 4
Pathology services table

4. The following table of pathology services is prescribed for the purposes of subsection 4A (2) of the Health Insurance Act 1973:
PATHOLOGY SERVICES TABLE
RULES OF INTERPRETATION
1. In this table:
"Division" means a Division of the list of services and fees in this table;
"item" means an item in that list;
"recognised pathologist" means a medical practitioner who under a determination under section 61, is recognised for the purposes of this Act as a specialist in the specialty of pathology.
2. If an item includes the symbol "(SP)", the item relates to a pathology service when rendered by or on behalf of an approved pathology practitioner who is a recognised pathologist other than a pathology service:
(a) rendered following a request made in the course of the provision of an out-patient service at a recognised hospital; or
(b) rendered following a request made in respect of a person who was, at the time when the request was made, a private patient in a recognised hospital; or
(c) in the rendering of which:
(i) any pathology equipment of a recognised hospital, or a laboratory included in a prescribed class of laboratories, is used; or
(ii) any member of the staff of a recognised hospital, or a laboratory included in a prescribed class of laboratories, participates in the course of that member's employment with that hospital or laboratory.
3. If an item includes the symbol "(OP)", the item is taken to relate to a pathology service other than a pathology service:
(a) to which an item that includes the symbol "(SP)" relates; or
(b) to which subsection 16A (7) applies.
4. For the purposes of rules 2 and 3, each of the following classes of laboratories is a prescribed class of laboratories:
(a) laboratories operated by the Commonwealth;
(b) laboratories operated by a State or an authority of a State;
(c) laboratories operated by the Northern Territory;
(d) laboratories operated by the Australian Capital Territory;
(e) laboratories operated by an Australian tertiary education institution.
5. 2 or more pathology services rendered following 2 or more requests are taken to have been rendered following a single request if:
(a) each pathology service is rendered to the same person; and
(b) each pathology service is listed in the same item; and
(c) the determinations of the necessity for the pathology services were made on the same day.
6. In rule 5, "service" includes an assay, estimation and test.
7. A reference in these rules to a request made to an approved pathology practitioner includes a reference to a request that is taken for the purposes of section 16A, to have been made to that approved pathology practitioner.
8. If:
(a) a pathology service (in this rule called the "first pathology service") is rendered following a request; and
(b) an item of the table applies to that pathology service; and
(c) another pathology service (in this rule called the "second pathology service") is rendered following the request; and
(d) the second pathology service is of a kind referred to in the item referred to in paragraph (b);
the second pathology service is treated as if it were subsumed within the first pathology service.
Example: Dr Proctor requests an extended blood grouping test (covered by item 1192) and the test includes a basic blood grouping test (covered by item 1187). Item 1187 is referred to in item 1192. Benefit is payble under item 1192 for the extended blood grouping test but benefit is not payable separately under item 1187 for the basic blood grouping test.

9. For the purposes of Division 1:
(a) if pathology services of a kind referred to in item 1187, 1188, 1192 or 1193 are rendered to a person during a period of hospitalisation, the item applies only to the first pathology service of that kind rendered to the person during that person's hospitalisation; and
(b) tests performed on material stored from a previous patient episode (except tests specified in item 1198 of 1199) in response to a later request are treated as being part or that previous patient episode if the second request is made within 14 days of that previous patient episode.
10. For the purposes of Division 2:
(a) if a pathology service involving the measurement of any substance in urine requires a 24 hour urine collection or calculation of a substance/creatinine ratio, that pathology service is treated as including any estimation of creatinine in other fluids necessary for calculation; and
(b) tests performed on material stored from a previous patient episode in response to a subsequent request are treated as being part of that previous patient episode if the second request occurs within 14 days of that previous patient episode.
11. For the purposes of Division 3:
(a) serial examinations or cultures means examinations or cultures requested on the 1 occasion regardless of whether the materials are received on different days by the approved pathology practitioner and regardless of whether the examinations or cultures were requested on 1 or more request forms by the treating practitioner; and
(b) tests performed on material that has been stored from a previous patient episode in response to a later request are treated as being part of that previous patient episode if the further request occurs within 14 days of that previous patient episode.
12. For the purposes of Division 4:
(a) tests performed on material that has been stored from a previous patient episode in response to a later request are treated as being part of that previous patient episode if the further request occurs within 14 days of that previous patient episode; and
(b) in items 2271, 2274, 2275, 2276, 2277, 2278, 2279 and 2280, the estimation of a single antibody includes qualitative and quantitative assays for that antibody.
13. For the purposes of Division 5:
(a) "biopsy material" means all tissue received by the approved pathology practitioner from any operation or group of operations performed on a patient at the same time other than a bone marrow biopsy; and
(b) if a pathology service relating to the examination of biopsy material is rendered under an item set out in Division 5 in circumstances where a further pathology service specified in an item in Division 5 is rendered also in relation to that biopsy material all those pathology services are treated as 1 pathology service under the same item appropriate to the pathology services provided.
14. For the purposes of Division 6, "serial examinations" means examinations requested on the same occasion regardless of whether the materials are received on different days by the approved pathology practitioner and regardless of whether the examinations were requested on 1 or more request forms by the treating practitioner.
15. If in these Rules provision is made for 2 or more pathology services to be treated as 1 pathology service, a reference to an appropriate item is a reference to the item that incorporates whichever of the symbols "(SP)" or "(OP)" is relevant to the rendering of that pathology service.
16. The lists of abbreviations at the end of the table are provided to allow users of the table to identify and refer to particular pathology services, or groups of pathology services, more accurately and efficiently.

SERVICES AND FEES
Item Pathology service Fee
$
Division 1 - Haematology
1163 Blood count consisting of erythrocyte count, C-reactive protein, erythrocyte sedimentation rate, blood viscosity, haematocrit, haemoglobin, platelet count, leucocyte count, reticulocyte count - 1 or 2
procedures (SP) 7.80
1164 Blood count consisting of erythrocyte count, C-reactive protein, erythrocyte sedimentation rate, blood viscosity, haematocrit, haemoglobin, platelet count, leucocyte count, reticulocyte count - 1 or 2
procedures (OP) 5.90
1168 3 or more procedures to which item 1163 applies, including any calculation or measurement of erythrocyte or other indices
(SP) 10.60
1169 3 or more procedures to which item 1164 applies, including any calculation or measurement of erythrocyte or other indices
(OP) 7.95
1170 Examination of blood film, with or without differential cell count, or differential cell count with or without examination of blood film, and if performed, any of these additional services - Direct Coombs test, tests for heterophile antibodies, cold agglutinins, examination of blood film by special stains to demonstrate Heinz bodies, parasites or iron, or examination of a blood film with alpha-naphthyl acetate esterase, choloroacetate esterase, neutrophil alkaline phosphotase, nitro blue tetrazolium, periodic acid Schiff, Sudan Black stains, or Kleihauer test for HbF on blood film, including any
services specified in item 1419 (SP) 14.00
1171 Examination of blood film, with or without differential cell count, or differential cell count with or without examination of blood film, and if performed, any of these additional services - Direct Coombs test, tests for heterophile antibodies, cold agglutinins, examination of blood film by special stains to demonstrate Heinz bodies, parasites or iron, or examination of a blood film with alpha-naphthyl acetate esterase, choloroacetate esterase, neutrophil alkaline phosphotase, nitro blue tetrazolium, periodic acid Schiff, Sudan Black stains, or Kleihauer test for HbF on blood film, inlcuding any
services specified in item 1420 (OP) 10.45
1172 Full blood examination consisting of items
1168 and 1170 (SP) 24.50
1173 Full blood examination consisting of items
1169 and 1171 (OP) 18.20
1176 Erythrocytes, qualitative or quantitative assessment of haemolysis or metabolic enzymes by - erythrocyte autohaemolysis test, erythrocyte fragility test, sugar water test, erythrocyte metabolic enzyme test, heat denaturation test, isopropanol precipitation test, acid haemolysis test, and quantitation of muramidase in serum or urine - 1 or more
procedures (SP) 32.00
1177 Erythrocytes, qualitative or quantitative assessment of haemolysis or metabolic enzymes by - erythrocyte autohaemolysis test, erythrocyte fragility test, sugar water test, erythrocyte metabolic enzyme test, heat denaturation test, isopropanol precipitation test, acid haemolysis test, and quantitation of muramidase in serum or urine - 1 or more
procedures (OP) 24.20
1179 Tests for the diagnosis of haemoglobinopathy consisting of haemoglobin electrophoresis and 2 of the following - examination for HbH, quantitation of HbA2 or HbF, including any service specified in item
1163, 1168, 1170 or 1172 (SP) 50.00
1180 Tests for the diagnosis of haemoglobinopathy consisting of haemoglobin electrophoresis and 2 of the following - examination for HbH, quantitation of HbA2 or HbF, including any service specified in item
1164, 1169, 1171 or 1173 (OP) 37.65
1181 Histopathological examination of sections of bone marrow trephine biopsy including where indicated, examination of marrow smears and any special stains and immuno-chemical techniques, including any service specified in item 1163, 1168, 1170, 1172 or 1183 (SP)
154.00
1182 Histopathological examination of sections of bone marrow trephine biopsy including where indicated, examination of marrow smears and any special stains and immuno-chemical techniques, including any service specified in item 1164, 1169, 1171, 1173 or 1184 (OP)
115.55
1183 Bone marrow examination of aspirated material including any special stains, immuno-chemical techniques and clot sections where necessary, including any service specified in,
item 1163, 1168, 1170 or 1172 (SP) 112.00
1184 Bone marrow examination of aspirated material including any special stains, immuno-chemical techniques and clot sections where necessary, including any service specified in
item 1164, 1169, 1171 or 1173 (OP) 83.90
1187 Blood grouping, including back-grouping
when performed - ABO and Rh (D antigen) (SP) 13.60
1188 Blood grouping, including back-grouping
when performed - ABO and Rh (D antigen) (OP) 10.15
1192 Blood grouping - Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system - one or more systems, including any service specified in
item 1187 (SP) 27.00
1193 Blood grouping - Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system - one or more systems, including any service specified in
item 1188 (OP) 20.25
1196 Blood grouping, including back-grouping when performed, and examination of serum for Rh and other blood group antibodies, including identification and quantitative estimation of any antibodies detected, and including any service specified in item 1163, 1168, 1170 or
1172 (SP) 50.00
1197 Blood grouping, including back-grouping when performed, and examination of serum for Rh and other blood group antibodies, including identification and quantitative estimation of any antibodies detected, and including any service specified in item 1164, 1169, 1171 or
1173 (OP) 37.65
1198 Compatibility testing, including all necessary grouping checks of patient and donor, examination for antibodies, identification and, if necessary, quantitative estimation of any antibodies detected and any service specified in item 1163, 1168, 1170, 1172, 1187 or 1196 including all testing
performed on any 1 day (SP) 122.00
1199 Compatibility testing, including all necessary grouping checks of patient and donor, examination for antibodies, identification and, if necessary, quantitative estimation of any antibodies detected and any service specified in item 1164, 1169, 1171, 1173, 1188 or 1197 including all testing
performed on any 1 day (OP) 91.80
1417 Examination of serum for blood group antibodies including identification and, if necessary, quantitative estimation of any
antibodies detected (SP) 22.00
1418 Examination of serum for blood group antibodies including identification and, if necessary, quantitative estimation of any
antibodies detected (OP) 16.65
1419 Direct Coombs test, qualitative or quantitative test for cold agglutinins, or heterophile antibodies, qualitative spectroscopic examination of blood for abnormal haemoglobins, qualitative test for red cell porphyrins and detection of metalbumin (Schumm's test) including service specified in item 1170 or 1172 - 1 or more
tests (SP) 12.20
1420 Direct Coombs test, qualitative or quantitative test for cold agglutinins, or heterophile antibodies, qualitative spectroscopic examination of blood for abnormal haemoglobins, qualitative test for red cell porphyrins and detection of metalbumin (Schumm's test) including service specified in item 1171 or 1173 - 1 or more
tests (OP) 9.20
1521 Skin bleeding time, coagulation time, prothrombin time, activated partial thromboplastin time, thrombin time (including test for presence of an inhibitor and serial tests for fibrinolysis), test for factor XIII deficiency, fibrinogen, or 1 of - fibrinogen degradation products, fibrin monomer or D-dimer
- 1 estimation (SP) 16.80
1522 Skin bleeding time, coagulation time, prothrombin time, activated partial thromboplastin time, thrombin time (including test for presence of an inhibitor and serial tests for fibrinolysis), test for factor XIII deficiency, fibrinogen, or 1 of - fibrinogen degradation products, fibrin monomer or D-dimer
- 1 estimation (OP) 12.70
1523 2 estimations specified in item 1521 (SP) 22.00
1524 2 estimations specified in item 1522 (OP) 16.65
1525 3 estimations specified in item 1521 (SP) 28.00
1526 3 estimations specified in item 1522 (OP) 21.00
1527 4 or more estimations specified in item
1521 (SP) 33.00
1528 4 or more estimations specified in item
1522 (OP) 25.00

1531 Quantitative assay, by 1 or more techniques, of plasminogen, antithrombin III, Protein C, Protein S, heparin co-factor II, Euglobulin clot lysis time and test for lupus
anticoagulant - 1 estimation (SP) 33.00
1532 Quantitative assay, by 1 or more techniques, of plasminogen, antithrombin III, Protein C, Protein S, heparin co-factor II, Euglobulin clot lysis time and test for lupus
anticoagulant - 1 estimation (OP) 25.00
1533 4 or more estimations specified in item
1531 (SP) 106.00
1534 4 or more estimations specified in item
1532 (OP) 79.15
1535 Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or similar substance
- 1 or more estimations (SP) 66.00
1538 Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or similar substance
- 1 or more estimations (OP) 49.85
1539 Heperin assay, only when monitoring a patient on subcutaneous heparin or low molecular weight heparin - 1 or more
estimations (SP) 44.50
1540 Heparin assay, only when monitoring a patient on subcutaneous heparin or low molecular weight heparin - 1 or more
estimations (OP) 33.25
1541 Quantitative assay of Von Willebrand's factor antigen (factor VIII related antigen), Von Willebrand's factor (ristocetin cofactor), factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald
factor, Passovy factor - 1 estimation (SP) 44.50
1542 Quantitative assay of Von Willebrand's factor antigen (factor VIII related antigen), Von Willebrand's factor (ristocetin cofactor), factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald
factor, Passovy factor - 1 estimation (OP) 33.25
1543 2 estimations as specified in item 1541
(SP) 66.00
1544 2 estimations as specified in item 1542
(OP) 49.85
1550 3 or more estimations as specified in item
1541 (SP) 83.00
1551 3 or more estimations as specified in item
1542 (OP) 62.55
Division 2 - Chemical Pathology
1558 Quantitative estimation in serum, plasma, urine or any other body fluid, by any method except by reagent strip with or without reflectance meter or electrophoresis of - alanine amino-transferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total and any fractions), calcium (total, dialysed or ionized), chloride, cholesterol, creatine kinase, creatine kinase isoenzymes (when not performed as specified in item 1734), creatinine, fructosamine, gamma glutamyl transpeptidase, globulin, glucose, lactate dehydrogenase, lipase, lithium, magnesium, phosphate, potassium, total protein, sodium, triglycerides, urate, urea -
1 estimation (SP) 14.00
1559 Quantitative estimation in serum, plasma, urine or any other body fluid, by any method except by reagent strip with or without reflectance meter or electrophoresis of - alanine amino-transferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total and any fractions), calcium (total, dialysed or ionized), chloride, cholesterol, creatine kinase, creatine kinase isoenzymes (when not performed as specified in item 1735), creatinine, fructosamine, gamma glutamyl transpeptidase, globulin, glucose, lactate dehydrogenase, lipase, lithium, magnesium, phosphate, potassium, total protein, sodium, triglycerides, urate, urea -
1 estimation (OP) 10.45
1560 2 estimations specified in item 1558 (SP) 16.80
1561 2 estimations specified in item 1559 (OP) 12.70
1562 3 estimations specified in item 1558 (SP) 19.60
1563 3 estimations specified in item 1559 (OP) 14.75
1564 4 estimations specified in item 1558 (SP) 22.00
1565 4 estimations specified in item 1559 (OP) 16.65
1569 5 estimations specified in item 1558 (SP) 25.00
1570 5 estimations specified in item 1559 (OP) 18.65
1571 6 or more estimations specified in item
1558 (SP) 28.00
1572 6 or more estimations specified in item
1559 (OP) 21.00
1575 Qualitative estimation by any method, except by reagent strip or dip-stick of the following urine constituents - bilirubin, cystine (cysteine), haemoglobin, melanin (melanogen), myoglobin, porphobilinogen, porphyrins, urobilinogen or pH measurement of body fluids other than urine (excepting urine acidification test), or cryoglobulins or cryofibrinogen in plasma - 1 or more
estimations (SP) 13.20
1576 Qualitative estimation by any method, except by reagent strip or dip-stick of the following urine constituents - bilirubin, cystine (cysteine), haemoglobin, melanin (melanogen), myoglobin, porphobilinogen, porphyrins, urobilinogen or pH measurement of body fluids other than urine (excepting urine acidification test), or cryoglobulins or cryofibrinogen in plasma - 1 or more
estimations (OP) 10.00
1577 Qualitative estimation by any method except by reagent strip or dip-stick of the following faecal constituents - haemoglobin, porphyrins, reducing substances - each estimation, to a maximum of 3 estimations,
taken on separate days (SP) 8.90
1578 Qualitative estimation by any method except by reagent strip or dip-stick of the following faecal constituents - haemoglobin, porphyrins, reducing substances - each estimation, to a maximum of 3 estimations,
taken on separate days (OP) 6.65
1579 Immunological tests for human haemoglobin in faeces performed in any 28 day period, including chemical test if performed - 1
estimation (SP) 16.80
1580 Immunological tests for human haemoglobin in faeces performed in any 28 day period, including chemical test if performed - 1
estimation (OP) 12.70
1581 2 or more estimations specified in item
1579 (SP) 38.50
1582 2 or more estimations specified in item,
1580 (OP) 28.95
1583 Osmolality, estimation by osmometer, in serum or in urine - 1 or more estimations
(SP) 33.00
1584 Osmolality, estimation by osmometer, in serum or in urine - 1 or more estimations
(OP) 25.00
1590 Quantitative estimation of blood gases including tests performed from - pO2, oxygen saturation, pCO2, bicarbonate, pH, and any other measurement (e.g. haemoglobin, potassium) or calculation performed on the same specimen - 1 or more estimation on 1
specimen (SP) 45.50
1591 Quantitative estimation of blood gases including tests performed from - pO2, oxygen saturation, pCO2, bicarbonate, pH, and any other measurement (e.g. haemoglobin, potassium) or calculation performed on the same specimen - 1 or more estimation on 1
specimen (OP) 34.05
1592 1 or more estimations of blood gases as specified in item 1590 on 2 or more specimens
within any 1 day (SP) 56.00
1593 1 or more estimations of blood gases as specified in item 1591 on 2 or more specimens
within any 1 day (OP) 41.95
1595 Calculus, analysis of 1 or more (SP)
41.00
1596 Calculus, analysis of 1 or more (OP) 30.90 1598 Drug or chemical assays - including all qualitative and quantitative tests on blood, urine or other body fluid for a drug or drugs of abuse, including illegal drugs and legally available drugs taken other than in appropriate dosage, ingested or absorbed toxic chemicals including any service specified in item 1712, 1714 or 1716, but excluding the surveillance of sports people and athletes for performance improving substances - 1 or more
assays (SP) 56.00
1599 Drug or chemical assays - including all qualitative and quantitative tests on blood, urine or other body fluid for a drug or drugs of abuse, including illegal drugs and legally available drugs taken other than in appropriate dosage, ingested or absorbed toxic chemicals including any service specified in item 1713, 1715 or 1717, but excluding the surveillance of sports people and athletes for performance improving substances - 1 or more
assays (OP) 41.95
1627 Drug assays - including all qualitative and quantitative estimations on blood, urine or other body fluid for a drug of abuse or a therapeutic drug on a sample collected from a patient participating in a drug abuse treatment programme, or being treated for drug effects or under a court order or parole board supervision, but excluding the detection of nicotine and metabolites in smoking withdrawal programmes - each assay to a maximum of 4
assays within any 28 day period (SP) 28.00
1628 Drug assays - including all qualitative and quantitative estimations on blood, urine or other body fluid for a drug of abuse or a therapeutic drug on a sample collected from a patient participating in a drug abuse treatment programme, or being treated for drug effects or under a court order or parole board supervision, but excluding the detection of nicotine and metabolites in smoking withdrawal programmes - each assay to a maximum of 4
assays within any 28 day period (OP) 21.00
1712 Drug assay - quantitative estimation on blood or other body fluid by any method of a drug being used therapeutically for the patient from whom the specimen was taken and not elsewhere specified in the Schedule - 1
estimation (SP) 28.00
1713 Drug assay - quantitative estimation on blood or other body fluid by any method of a drug being used therapeutically for the patient from whom the specimen was taken and not elsewhere specified in the Schedule - 1
estimation (OP) 21.00
1714 2 estimations specified in item 1712 (SP) 38.50
1715 2 estimations specified in item 1713 (OP) 28.95
1716 3 or more estimations specified in item
1712 (SP) 50.00
1717 3 or more estimations specified in item
1713 (OP) 37.65
1726 Amniotic fluid, spectrophotometric examination of, estimation of lecithin/sphingomyelin ratio, palmitic acid, phosphatidylglycerol or lamellar body phospholipid - 1 or more examinations or
estimations (SP) 44.50
1727 Amniotic fluid, spectrophotometric examination of, estimation of lecithin/sphingomyelin ratio, palmitic acid, phosphatidylglycerol or lamellar body phospholipid - 1 or more examinations or
estimations (OP) 33.25
1734 Electrophoresis, quantitative or qualitative of serum, urine or other body fluid to demonstrate protein classes or presence and amount of paraprotein, or the isoenzymes of lactate dehydrogenase, alkaline phosphatase and creatine kinase or lipoprotein electrophoresis (only when the Cholesterol is >6.5mmol/l and Triglyceride >3.0 mmol/l or in the diagnosis of types III and IV hyperlipidemia), including the preliminary quantitation of total protein, albumin and globulin or of total relevant enzyme activity - 1 examination to a maximum of 2 examinations
in any 12 month period (SP) 41.00
1735 Electrophoresis, quantitative or qualitative of serum, urine or other body fluid to demonstrate protein classes or presence and amount of paraprotein, or the isoenzymes of lactate dehydrogenase, alkaline phosphatase and creatine kinase or lipoprotein electrophoresis (only when the Cholesterol is >6.5 mmol/l and Triglyceride >3.0 mmol/l or in the diagnosis of types III and IV hyperlipidemia), including the preliminary quantitation of total protein, albumin and globulin or of total relevant enzyme activity - 1 examination to a maximum of 2 examinations
in any 12 month period (OP) 30.90
1736 Electrophoresis, quantitative or qualitative of concurrently collected, or collected within a 28 day period, serum, urine or other body fluid to demonstrate protein classes or presence and amount of paraprotein, including the preliminary quantitation of total protein, albumin and globulin, or of total relevant enzyme activity - 2 or more
examinations (SP) 61.00
1737 Electrophoresis, quantitative or qualitative of concurrently collected, or collected within a 28 day period, serum, urine or other body fluid to demonstrate protein classes or presence and amount of paraprotein, including the preliminary quantitation of total protein, albumin and globulin, or of total relevant enzyme activity - 2 or more
examinations (OP) 45.90
1738 Alpha-feto protein, Alpha-1 antitrypsin, Alpha-2 macroglobulin, beta-2 microglobulin, C-1 esterase inhibitor, Caeruloplasmin, Ferritin (unless specified in item 1752), Haptoglobins, Microalbumin (in proven diabetes mellitus), Prealbumin, Prostate Specific Antigen, Prostatic Acid Phosphatase, Transferrin (unless specified in item 1752) and, in the follow-up of proven malignancy, Mucin-like carcinoma associated antigen, CA-125 antigen, CA-19.9 antigen, CA-15.3 antigen, Carcinoembryonic antigen, Mammary serum antigen, Neuron specific enolase, SCC Related antigen, Thyroglobulin - quantitative estimation in serum, urine or
other body fluid - 1 estimation (SP) 27.00

1739 Alpha-feto protein, Alpha-1 antitrypsin, Alpha-2 macroglobulin, beta-2 microglobulin, C-1 esterase inhibitor, Caeruloplasmin, Ferritin (unless specified in item 1753), Haptoglobins, Microalbumin (in proven diabetes mellitus), Prealbumin, Prostate Specific Antigen, Prostatic Acid Phosphatase, Transferrin (unless specified in item 1753) and, in the follow up of proven malignancy, Mucin-like carcinoma associated antigen, CA-125 antigen, CA-19.9 antigen, CA-15.3 antigen, Carcinoembryonic antigen, Mammary serum antigen, Neuron specific enolase, SCC Related antigen, Thyroglobulin - quantitative estimation in serum, urine or other body fluid
- 1 estimation (OP) 20.25
1740 2 or more estimations specified in item
1738 (SP) 50.00
1741 2 or more estimations specified in item
1739 (OP) 37.65
1752 Iron studies consisting of quantitative analysis of iron, transferrin or iron binding
capacity and ferritin (SP) 53.00
1753 Iron studies consisting of quantitative analysis of iron, transferrin or iron binding
capacity and ferritin (OP) 39.60
1768 Serum B12, serum folate - 1 or more
estimations within any 28 day period (SP) 33.00
1769 Serum B12, serum folate - 1 or more
estimations within any 28 day period (OP) 25.00
1770 Red cell folate and serum B12 and, if required, serum folate, to a maximum of 3
estimations in any 12 month period (SP) 61.00
1771 Red cell folate and serum B12 and, if required, serum folate, to a maximum of 3
estimations in any 12 month period (OP) 45.40
1780 Vitamins, quantitative estimation in blood, urine or other body fluid, by direct or indirect means, of Vitamins A, B1, B2, B3, B6, C, and E - 1 or more estimations within any 6
month period (SP) 41.00
1783 Vitamins, quantitative estimation in blood, urine or other body fluid, by direct or indirect means, of Vitamins A, B1, B2, B3, B6, C, and E - 1 or more estimations within any 6
month period (OP) 30.90
1786 Vitamin D or D fractions - 1 or more
estimations (SP) 41.00
1787 Vitamin D or D fractions - 1 or more
estimations (OP) 30.90
1791 Acetoacetate, alcohol, aminoacids, ammonia, angiotensin converting enzyme, betahydroxybutyrate, cholinesterase, cystine (cysteine), total free fatty acids, histamine, hydroxyindoleacetic acid, hydroxyproline, lactate, neonatal bilirubin (1 or more fractions), oxalate, pyruvate, serotonin,
xylose, zinc - 1 quantitative estimation (SP) 33.00
1792 Acetoacetate, alcohol, aminoacids, ammonia, angiotensin converting enzyme, betahydroxybutyrate, cholinesterase, cystine (cysteine), total free fatty acids, histamine, hydroxyindoleacetic acid, hydroxyproline, lactate, neonatal bilirubin (1 or more fractions), oxalate, pyruvate, serotonin,
xylose, zinc - 1 quantitative estimation (OP) 25.00
1795 2 or more estimations specified in item
1791 (SP) 52.00
1798 2 or more estimations specified in item
1792 (OP) 39.20
1871 Aluminium, arsenic, beryllium, cadmium, copper, chromium, gold, manganese, mercury, nickel, selenium, strontium - in blood, urine or other body fluid or tissue - 1 or more
estimations within any 6 month period (SP) 47.00
1872 Aluminium, arsenic, beryllium, cadmium, copper, chromium, gold, manganese, mercury, nickel, selenium, strontium - in blood, urine or other body fluid or tissue - 1 or more
estimations within any 6 month period (OP) 35.25
1895 Blood lead estimation, other than for occupational health screening purposes, to a maximum of 3 estimations in any 6 month period
- each estimation (SP) 41.00
1896 Blood lead estimation, other than for occupational health screening purposes, to a maximum of 3 estimations in any 6 month period
- each estimation (OP) 30.90
1959 Porphyrins (1 or more fractions), Catecholamines (1 or more fractions), Hydroxy Methoxy Mandelic Acid (HMMA), Homovanillic Acid (HVA), Metanephrines, Methoxy Hydroxy Phenylethylene Glycol (MHPG), Phenyl Acetic Acid (PAA) - quantitative including any qualitative estimations - 1 or more
estimations (SP) 54.00
1960 Porphyrins (1 or more fractions), Catecholamines (1 or more fractions), Hydroxy Methoxy Mandelic Acid (HMMA), Homovanillic Acid (HVA), Metanephrines, Methoxy Hydroxy Phenylethylene Glycol (MHPG), Phenyl Acetic Acid (PAA) - quantitative including any qualitative estimations - 1 or more
estimations (OP) 40.40
1963 Faecal fat, Breath Hydrogen measurements in response to loading with disaccharides - 1 or more quantitative estimations within any 28
day period (SP) 54.00
1964 Faecal fat, Breath Hydrogen measurements in response to loading with disaccharides - 1 or more quantitative estimations within any 28
day period (OP) 40.40
1969 Solid tissue or tissues excluding blood
elements - assay of 1 or 2 enzymes (SP) 54.00
1970 Solid tissue or tissues excluding blood
elements - assay of 1 or 2 enzymes (OP) 40.40
1975 Assay of 3 to 5 enzymes as specified in
item 1969 (SP) 100.00
1976 Assay of 3 to 5 enzymes as specified in
item 1970 (OP) 75.20
1977 Assay of 6 or more enzymes as specified in
item 1969 (SP) 132.00
1978 Assay of 6 or more enzymes as specified in
item 1970 (OP) 99.70
1983 Thyroid function tests, including thyrotrophin (TSH) and at least 1 or more of the following tests - free thyroxine index, free thyroxine, free T3, total T3, thyroxine
binding globulin (SP) 56.00
1984 Thyroid function tests, including thyrotrophin (TSH) and at least 1 or more of the following tests - free thyroxine index, free thyroxine, free T3, total T3, thyroxine
binding globulin (OP) 41.95
1985 Thyrotrophin releasing hormone (TRH) test, including provision and administration of TRH and all necessary estimations of hormones
(SP) 66.00
1986 Thyrotrophin releasing hormone (TRH) test, including provision and administration of TRH and all necessary estimations of hormones
(OP) 49.85
1989 Growth hormone suppression by glucose loading, Growth hormone stimulation by exercise, Dexamethasone suppression test, L-Dopa stimulation of growth hormone, where physically performed by a recognised
pathologist - 1 or more procedures (SP) 15.80
1990 Growth hormone suppression by glucose loading, Growth hormone stimulation by exercise, Dexamethasone suppression test, L-Dopa stimulation of growth hormone, where physically performed by a recognised
pathologist - 1 or more procedures (OP) 11.90
1991 Gonadotrophin releasing hormone stimulation test, Synacthen stimulation test, Glucagon stimulation test with C-peptide measurement, Pentagastrin stimulation of thyrocalcitonin release, Secretin stimulation of gastrin release, Insulin hypoglycaemia, Arginine infusion, where physically performed by a recognised pathologist - 1 procedure
(SP) 53.00
1992 Gonadotrophin releasing hormone stimulation test, Synacthen stimulation test, Glucagon stimulation test with C-peptide measurement, Pentagastrin stimulation of thyrocalcitonin release, Secretin stimulation of gastrin release, Insulin hypoglycaemia, Arginine infusion, where physically performed by a recognised pathologist - 1 procedure
(OP) 39.60
1993 2 or more tests specified in item 1991
(SP) 84.00
1994 2 or more tests specified in item 1992
(OP) 63.30
2021 Hormones and hormone binding proteins, quantitative estimation by any method of: ACTH, Aldosterone, Androstenedione, C-peptide, Calcitonin, Cortisol, Cyclic AMP, DHEAS, 11-Deoxycortisol, Dihydrotestosterone, FSH, Gastrin, Glucagon, Growth hormone, Human Placental Lactogen, Hydroxyprogesterone, Insulin, LH, Oestradiol, Oestriol, Oestrone, Progesterone, Prolactin, PTH, Renin, Sex hormone binding globulin, Somatomedin C(IgF1), free or total Testosterone, TSH (where not requested as part of a thyroid function test), Urine steroid fraction or fractions, Vasoactive intestinal peptide, Vasopressin
(anti-diuretic hormone) - 1 estimation (SP) 38.50
2024 Hormones and hormone binding proteins, quantitative estimation by any method of: ACTH, Aldosterone, Androstenedione, C-peptide, Calcitonin, Cortisol, Cyclic AMP, DHEAS, 11-Deoxycortisol, Dihydrotestosterone, FSH, Gastrin, Glucagon, Growth hormone, Human Placental Lactogen, Hydroxyprogesterone, Insulin, LH, Oestradiol, Oestriol, Oestrone, Progesterone, Prolactin, PTH, Renin, Sex hormone binding globulin, Somatomedin C(IgF1), free or total Testosterone, TSH (where not requested as part of a thyroid function test), Urine steroid fraction or fractions, Vasoactive intestinal peptide, Vasopressin
(anti-diuretic hormone) - 1 estimation (OP) 28.95
2025 2 estimations specified in item 2021 (SP) 61.00
2026 2 estimations specified in item 2024 (OP) 45.90
2027 3 estimations specified in item 2021 (SP) 77.00
2028 3 estimations specified in item 2024 (OP) 57.80
2029 4 estimations specified in item 2021 (SP) 94.00
2030 4 estimations specified in item 2024 (OP) 70.45
2031 5 estimations specified in item 2021 (SP) 106.00
2032 5 estimations specified in item 2024 (OP) 79.15
2033 6 or more estimations specified in item
2021 (SP) 118.00
2034 6 or more estimations specified in item
2024 (OP) 88.65
2037 Hormone receptor assay on proven primary breast carcinoma or subsequent lesion in the breast or metastasis from a breast carcinoma -
1 or more assays (SP) 108.00
2038 Hormone receptor assay on proven primary breast carcinoma or subsequent lesion in the breast or metastasis from a breast carcinoma -
1 or more assays (OP) 80.75
2039 HDL Cholesterol, estimation of, in patients with serum cholesterol ;a75.5mmol/l or those on prescribed lipid lowering drugs - each estimation to a maximum of 4 estimations
in any 12 month period (SP) 16.80
2040 HDL cholesterol, estimation of, in patients with serum cholesterol ;a75.5mmol/l or those on prescribed lipid lowering drugs - each estimation to a maximum of 4 estimations
in any 12 month period (OP) 12.70
2043 Glycosylated haemoglobin only when performed in the management of established diabetes - each estimation to a maximum of 4
estimations in any 12 month period (SP) 22.50
2044 Glycosylated haemoglobin only when performed in the management of established diabetes - each estimation to a maximum of 4
estimations in any 12 month period (OP) 17.05
Division 3 - Microbiology
2083 Microscopic examination of material other than blood, from 1 or more sites, obtained directly from a patient and excluding material from cultures - wet film, including differential cell count if performed, examination for dermatophytes or dark ground illumination, or stained preparation or preparations using any relevant stain or
stains - 1 or more examinations (SP) 10.00
2084 Microscopic examination of material other than blood, from 1 or more sites, obtained directly from a patient and excluding material from cultures - wet film, including differential cell count if performed, examination for dermatophytes or dark ground illumination, or stained preparation or preparations using any relevant stain or
stains - 1 or more examinations (OP) 7.55
2085 Microscopic examination of faeces for parasites using concentration techniques including the use of appropriate stains, to a maximum of 3 estimations taken on separate days including any service specified in item
2083 - each estimation (SP) 16.80
2086 Microscopic examination of faeces for parasites using concentration techniques including the use of appropriate stains, to a maximum of 3 estimations taken on separate days including any service specified in item
2084 - each estimation (OP) 12.70
2087 The cultural examination and microscopical examination when indicated (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic micro-organisms, including fungi but excluding viruses, from nasal swabs, throat swabs, eye swabs and ear swabs, including pathogen identification and antibiotic sensitivity testing, including any service specified in item 2083 - 1 or more
sites (SP) 26.50
2088 The cultural examination and microscopical examination when indicated (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic micro-organisms, including fungi but excluding viruses, from nasal swabs, throat swabs, eye swabs and ear swabs, including pathogen identification and antibiotic sensitivity testing, including any service specified in item 2084 - 1 or more
sites (OP) 19.80

2089 Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic micro-organisms, including fungi but excluding viruses, from the following sites - skin or other superficial sites, urethra, vagina, cervix or rectum (except for faecal pathogens), or specimens of sputum (except when part of item 2119), including pathogenic identification and antibiotic sensitivity testing, including any service specified in item 2083 or 2087 - 1 or more examinations on
1 or more specimens (SP) 38.50
2090 Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic micro-organisms, including fungi but excluding viruses, from the following sites: skin or other superficial sites, urethra, vagina, cervix or rectum (except for faecal pathogens), or specimens of sputum (except where part of item 2120), including pathogenic identification and antibiotic sensitivity testing, including any service specified in item 2084 or 2088 - 1 or more examinations on
1 or more specimens (OP) 28.95
2098 Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) of post-operative wounds, aspirations of body cavities, synovial fluid CSF and operative or biopsy specimens for the presence of pathogenic micro-organisms, including fungi but excluding viruses, involving aerobic and anaerobic culture and the use of different culture media and including pathogen identification and antibiotic sensitivity testing, including any service specified in item 2083, 2087 or 2089 - 1 or more sites
(SP) 52.00
2099 Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) of post-operative wounds, aspirations of body cavities, synovial fluid CSF and operative or biopsy specimens for the presence of pathogenic micro-organisms, including fungi but excluding viruses, involving aerobic and anaerobic culture and the use of different culture media and including pathogen identification and antibiotic sensitivity testing, including any service specified in item 2084, 2088 or 2090 - 1 or more sites
(OP) 39.20
2117 Cultural examination (including the detection of Clostridial toxins or antigens not elsewhere specified in the Schedule) of faeces to determine the presence or absence of faecal pathogens, involving the use of at least 2 selective or enrichment media as well as culture in at least 2 different atmospheres and including pathogen identification and antibiotic sensitivity testing, including any service specified in item 2083, to a maximum of 3 specimens in any 7 day period - each
examination (SP) 63.00
2118 Cultural examination (including the detection of Clostridial toxins or antigens not elsewhere specified in the Schedule) of faeces to determine the presence or absence of faecal pathogens, involving the use of at least 2 selective or enrichment media as well as culture in at least 2 different atmospheres and including pathogen identification and antibiotic sensitivity testing, including any service specified in item 2084, to a maximum of 3 specimens in any 7 day period - each
examination (OP) 47.50
2119 Microscopy with appropriate stains and cultural examinations of 3 specimens of sputum, urine or other bodily fluids for mycobacteria and any other bacterial pathogens, including pathogen identification and antibiotic sensitivity testing and including any service specified in item 2083
(SP) 89.00
2120 Microscopy with appropriate stains and cultural examinations of 3 specimens of sputum, urine or other bodily fluids for mycobacteria and any other bacterial pathogens, including pathogen identification and antibiotic sensitivity testing and including any service specified in item 2084
(OP) 66.50
2123 Blood culture to determine the presence or absence of pathogenic micro-organisms excluding viruses, including serial cultures and sub-cultures, any relevant cultural methods and any tests necessary to identify any cultured pathogen and necessary antibiotic sensitivity testing - each set of cultures to
a maximum of 3 sets (SP) 23.00
2124 Blood culture to determine the presence or absence of pathogenic micro-organisms excluding viruses, including serial cultures and sub-cultures, any relevant cultural methods and any tests necessary to identify any cultured pathogen and necessary antibiotic sensitivity testing - each set of cultures to
a maximum of 3 sets (OP) 17.45
2127 Urine examination including serial examination, with cell count, relevant stained preparations, culture, colony count by any method, identification of any cultured pathogens, antibiotic sensitivity testing when necessary, and with any relevant general examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts. (Simple culture by dip slide is
excluded from this item) (SP) 28.00
2128 Urine examination including serial examination, with cell count, relevant stained preparations, culture, colony count by any method, identification of any cultured pathogens, antibiotic sensitivity testing when necessary, and with any relevant general examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts. (Simple culture by dip slide is
excluded from this item) (OP) 21.00
2129 Direct detection of the antigens of Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Group B streptococcus (in CSF and urine specimens only), RSV, cryptococcal antigens and Varicella zoster or detection of Clostridium difficile toxin except where item 2117 has
been performed - 1 or more estimations (SP) 22.00
2130 Direct detection of the antigens of Heamophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Group B streptococcus (in CSF and urine specimens only), RSV, cryptococcal antigens and Varcella zoster or detection of Clostridium difficile toxin except where item 2118 has been
performed - 1 or more estimations (OP) 16.65
2133 Direct detection of Chlamydia from clinical material, not cultures - 1 or more
estimations (SP) 13.20
2134 Direct detection of Chlamydia from clinical material, not cultures - 1 or more
estimations (OP) 10.00
2135 Direct detection of Herpes simplex from clinical material, not cultures - 1 or more
estimations (SP) 13.20
2136 Direct detection of Herpes simplex from clinical material, not cultures - 1 or more
estimations (OP) 10.00
2139 Investigation for Herpes simplex virus (1 or more types) or Chlamydia trachomatis, in material obtained directly from a patient, by 1 or more cultural methods, including any
service specified in item 2133 or 2135 (SP) 38.50
2140 Investigation for Herpes simplex virus (1 or more types) or Chlamydia trachomatis, in material obtained directly from a patient, by 1 or more cultural methods, including any
service specified in item 2134 or 2136 (OP) 28.95
2145 Serology including IgG and IgM estimations of Rubella, toxoplasma or CMV when performed
during pregnancy - 1 or more assays (SP) 18.80
2146 Serology including IgG and IgM estimations of Rubella, toxoplasma or CMV when performed
during pregnancy - 1 or more assays (OP) 14.10
2181 Antibodies to microbial or exogenous antigens not elsewhere specified in the
Schedule - estimation of 1 antibody (SP) 18.80
2182 Antibodies to microbial or exogenous antigens not elsewhere specified in the
Schedule - estimation of 1 antibody (OP) 14.10
2183 2 estimations specified in item 2181 (SP) 29.00
2184 2 estimations specified in item 2182 (OP) 21.80
2185 3 estimations specified in item 2181 (SP) 38.50
2186 3 estimations specified in item 2182 (OP) 28.95
2187 4 estimations specified in item 2181 (SP) 48.50

2188 4 estimations specified in item 2182 (OP) 36.40
2189 5 estimations specified in item 2181 (SP) 59.00
2190 5 estimations specified in item 2182 (OP) 44.35
2191 6 or more estimations specified in item
2181 (SP) 69.00
2192 6 or more estimations specified in item
2182 (OP) 51.45
2221 Hepatitis B surface antigen test (SP) 18.80
2222 Hepatitis B surface antigen test (OP) 14.10
2223 Hepatitis B serology to define the immune status of an individual, including at least Hepatitis B surface antibody or Hepatitis B core antibody tests, including service
specified in item 2221, 2229 or 2231 (SP) 25.35
2224 Hepatitis B serology to define the immune status of an individual, including at least Hepatitis B surface antibody or Hepatitis B core antibody tests, including service
specified in item 2222, 2230 or 2232 (OP) 19.00
2229 All serological tests performed for the identification of the agent causing acute Hepatitis, which must include Hepatitis B surface antigen, Hepatitis B core antibody and Hepatitis A IgM antibody tests and those service specified in item 2221, 2223 or 2231
(SP) 50.15
2230 All serological tests performed for the identification of the agent causing acute Hepatitis, which must include Hepatitis B surface antigen, Hepatitis B core antibody and Hepatitis A IgM antibody tests and those services specified in item 2222, 2224 or 2232
(OP) 37.65
2231 All tests performed in the follow up of a patient with proven Hepatitis B, including Hepatitis B surface antigen and either Hepatitis Be antigen or Hepatitis B surface antibody tests, including services specified
in item 2221 or 2223 (SP) 36.40
2232 All tests performed in the follow up of a patient with proven Hepatitis B, including Hepatitis B surface antigen and either Hepatitis Be antigen or Hepatitis B surface antibody tests, including services specified
in item 2222 or 2224 (OP) 27.35
2235 Antibiotics or anti-microbial chemo-therapeutic agents, concentration in serum, urine or other body fluid, by direct quantitative measurement of the agent - 1 or
more estimations (SP) 33.25
2236 Antibiotics or anti-microbial chemo-therapeutic agents, concentration in serum, urine or other body fluid, by direct quantitative measurement of the agent - 1 or more estimations (OP) 25.00
Division 4 - Immunology
2239 Examination for, and identification of, a paraprotein (not previously identified), the presence of which is suggested by other tests (eg item 1734, 1736 or 2245), on serum, urine or other body fluid, or examination of CSF for oligoclonal proteins by immunoelectrophoresis
or immunofixation - 1 or more procedures (SP) 41.15
2240 Examination for, and identification of, a paraprotein (not previously identified), the presence of which is suggested by other tests (eg item 1735, 1737 or 2246), on serum, urine or other body fluid, or examination of CSF for oligoclonal proteins by immunoelectrophoresi
or immunofixation - 1 or more procedures (OP) 30.90
2241 Examination for, and identification of, a paraprotein (not previously identified), the presence of which is suggested by other tests (eg item 1734, 1736 or 2245) on serum and urine concurrently collected - 2 or more
procedures (SP) 61.20
2242 Examination for, and identification of, a paraprotein (not previously identified), the presence of which is suggested by other tests (eg item 1735, 1737 or 2246) on serum and urine concurrently collected - 2 or more
procedures (OP) 45.90
2245 Immunoglobulins G, A, M or D, quantitative estimation in serum, urine or other body fluid, by any method - estimation of 1
immunoglobin (SP) 20.05
2246 Immunoglobulins G, A, M or D, quantitative estimation in serum, urine or other body fluid, by any method - estimation of 1
immunoglobin (OP) 15.05
2251 2 estimations specified in item 2245 (SP) 31.15
2252 2 estimations specified in item 2246 (OP) 23.40
2253 3 or more estimations specified in item
2245 (SP) 42.20
2254 3 or more estimations specified in item
2246 (OP) 31.65
2255 Subclasses of Immunoglobulin G, 1 to 4, estimation where there is a reduced level of clinical significance of either total IgG or
IgA - 1 or more estimation (SP) 61.20
2256 Subclasses of Immunoglobulin G, 1 to 4, estimation where there is a reduced level of clinical significance of either total IgG or
IgA - 1 or more estimation (OP) 45.90

2257 Immunoglobulin E (total), quantitative estimation by any method or methods, with a maximum of 2 estimations in any 12 month
period (SP) 35.35
2258 Immunoglobulin E (total), quantitative estimation by any method or methods, with a maximum of 2 estimations in any 12 month
period (OP) 26.60
2259 Specific IgG or IgE antibodies to potential allergens - 1 or more tests for single or multiple allergens with a maximum of
4 estimations in any 12 month period (SP) 32.20
2260 Specific IgG or IgE antibodies to potential allergens - 1 or more tests for single or multiple allergens with a maximum of
4 estimations in any 12 month period (OP) 24.20
2261 Antinuclear antibodies, detection in serum or other body fluids, including quantitation
if required (SP) 33.25
2262 Antinuclear antibodies, detection in serum or other body fluids, including quantitation
if required (OP) 25.00
2263 Measurment of DNA binding (by Farr or equivalent assay, but excluding the Crithidia method), performed only where a positive antinuclear antibody titre of 1:40 or greater
has been obtained (SP) 40.65
2266 Measurement of DNA binding (by Farr or equivalent assay, but excluding the Crithidia method), performed only where a positive antinuclear antibody titre of 1:40 or greater
has been obtained (OP) 30.45
2267 Antibodies to extractable nuclear antigens, detection of in serum or other body
fluids (SP) 28.00
2268 Antibodies to extractable nuclear antigens, detection of in serum or other body
fluids (OP) 21.00
2269 Characterization of antibodies to extractable nuclear antigens, performed only where a positive result is obtained including
services specified in item 2267 (SP) 44.35
2270 Charaterization of antibodies to extractable nuclear antigens, performed only where a positive result is obtained including
services specified in item 2268 (OP) 33.25
2271 Antibodies to tissue antigens that are not elsewhere specified in an item in the Schedule
- estimation of 1 antibody (SP) 33.25
2274 Antibodies to tissue antigens which are not elsewhere specified in an item in the
Schedule - estimation of 1 antibody (OP) 25.00
2275 2 estimations specified in item 2271 (SP) 38.55
2276 2 estimations specified in item 2274 (OP) 28.95
2277 3 estimations specified in item 2271 (SP) 44.35
2278 3 estimations specified in item 2274 (OP) 33.25
2279 4 or more estimations specified in item
2271 (SP) 50.15
2280 4 or more estimations specified in item
2274 (OP) 37.65
2281 Rheumatoid factor, detection of by any
technique (SP) 13.30
2282 Rheumatoid factor, detection of by any
technique (OP) 10.00
2283 Quantitation of Rheumatoid factor where detected, including services specified in item
2281 (SP) 26.40
2284 Quantitation of Rheumatoid factor where detected, including services specified in item
2282 (OP) 19.80
2289 Complement - total and components - 1
quantitative estimation (SP) 22.20
2290 Complement - total and components - 1
quantitative estimation (OP) 16.65
2291 2 estimations as specified in item 2289
(SP) 33.25
2292 2 estimations as specified in item 2290
(OP) 25.00
2293 3 or more estimations as specified in
item 2289 (SP) 44.35
2312 3 or more estimations as specified in
item 2290 (OP) 33.25
2313 Leucocyte fractionation as a preliminary to leucocyte marker or leucocyte function
tests (SP) 41.15
2314 Leucocyte fractionation as a preliminary to leucocyte marker or leucocyte function
tests (OP) 30.90
2315 Functional tests for leucocytes, including use of all appropriate techniques (except E. rosette technique or similar) and any test specified in Division 1 - Haematology in the
Schedule (SP) 69.65
2316 Functional tests for leucocytes, including use of all appropriate techniques (except E. rosette technique or similar) and any test specified in Division 1 - Haematology in the
Schedule (OP) 52.25
2317 Leucocyte surface marker characterization by immunofluorescence or immunoenzyme techniques to assess lymphoid populations using a minimum of 3 monoclonal antibodies, including any services in item 2319 - 1 or
more estimations (SP) 88.65
2318 Leucocyte surface marker characterization by immunofluorescence or immunoenzyme techniques to assess lymphoid populations using a minimum of 3 monoclonal antibodies, including any service in item 2320 - 1 or more
estimations (OP) 66.50
2319 Leucocyte surface marker characterization by immunofluorescence or immunoenzyme techniques in the investigation of a probable haematological malignancy using a minimum of 7 monoclonal antibodies, including any services
in item 2317 - 1 or more estimations (SP) 211.00
2320 Leucocyte surface marker characterization by immunofluorescence or immunoenzyme techniques in the investigation of a probable haematological malignancy using a minimum of 7 monoclonal antibodies, including any service
in item 2318 - 1 or more estimations (OP) 158.25
2321 HLA typing comprising A, B, C and DR
phenotypes (SP) 93.90
2322 HLA typing comprising A, B, C and DR
phenotypes (OP) 70.45
2323 HLA typing, excluding any service specified in item 2321 - 1 or more antigens
(SP) 38.55
2324 HLA typing, excluding any service specified in item 2322 - 1 or more antigens
(OP) 28.95
2325 Mantoux test (SP) 13.30
2326 Mantoux test (OP) 10.00
Division 5 - Histopathology
2327 Histopathology examination of biopsy material including all tissue processing, staining and professional opinion or opinions
(SP) 93.90
2328 Histopathology examination of biopsy material including all tissue processing, staining and professional opinion or opinions
(OP) 70.45
2329 Immediate frozen section diagnosis of biopsy material, including any other
histopathology examination (SP) 175.15
2330 Immediate frozen section diagnosis of biopsy material, including any other
histopathology examination (OP) 131.35
2331 Immunohistochemical investigation of biopsy material by one or more of immunofluorescent, immunoperoxidase or other labelled antibody techniques including any
other histopathology examination (SP) 132.95
2332 Immunohistochemical investigation of biopsy material by one or more of immunofluorescent, immunoperoxidase or other labelled antibody techniques including any
other histopathology examination (OP) 99.70
2333 Electron microscopy of biopsy material including any other histopathology examination (SP) 141.40
2337 Electron microscopy of biopsy material including any other histopathology examination (OP) 106.05
Division 6 - Cytopathology
2338 Cytological examination of smears from cervix or vagina for detection of pre-cancerous or cancerous changes - 1 or more examinations (SP) 20.50
2339 Cytological examination of smears from cervix or vagina for detection of pre-cancerous or cancerous changes - 1 or more
examinations (OP) 15.40
2340 Cytological examination including serial examinations of smears from skin, nipple discharge, lip, mouth, nose or anus for detection of pre-cancerous or cancerous
changes - 1 or more examinations (SP) 20.50
2341 Cytological examination including serial examinations of smears from skin, nipple discharge, lip, mouth, nose or anus for detection of pre-cancerous or cancerous
changes - 1 or more examinations (OP) 15.40
2343 Cytological examination including serial examinations for malignant cells of body fluids, sputum (single specimen), urine (single specimen), washings or brushings not specified in item 2340 and any histopathological service performed on that
cytology specimen - 1 or more examinations (SP) 40.10
2344 Cytological examination including serial examinations for malignant cells of body fluids, sputum (single specimen), urine (single specimen), washings or brushings not specified in item 2341 and any histopathological service performed on that cytology specimen - 1 or more examinations
(OP) 30.10
2348 Cytological examination including examination of a series of 3 sputum or urine
specimens for malignant cells (SP) 83.35
2349 Cytological examination including examination of a series of 3 sputum or urine
specimens for malignant cells (OP) 62.55
2350 Cytological examination of material obtained from a patient by fine needle
aspiration of solid tissue or tissues (SP) 50.15
2351 Cytological examination of material obtained from a patient by fine needle
aspiration of solid tissue or tissues (OP) 37.65
2355 Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues where the aspiration is performed by a recognised pathologist or where a recognised pathologist attends the aspiration and performs cytological examination during the attendance
(SP) 93.90
2356 Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues where the aspiration is performed by a recognised pathologist or where a recognised pathologist attends the aspiration and performs cytological examination during the attendance
(OP) 70.45
Division 7 - Cytogenetics
2360 Chromosome studies, including preparation, count and karyotyping of 1 or more of amniotic fluid, bone marrow, skin and any other tissue
or fluid excluding blood - 1 or more estimations (SP) 181.50
2361 Chromosome studies, including preparation, count and karyotyping of 1 or more of amniotic fluid, bone marrow, skin and any other tissue or fluid excluding blood - 1 or more
estimations (OP) 136.10
2363 Chromosome studies, including preparation,
count and karyotyping of blood (SP) 164.60
2364 Chromosome studies, including preparation,
count and karyotyping of blood (OP) 123.45
2365 Chromosome identification by banding techniques (using fluorescein, Giemsa, or centromere staining or high resolution analysis) or by fragile X-site determination -
1 or more identifications (SP) 141.40
2366 Chromosome identification by banding techniques (using fluorescein, Giemsa, or centromere staining or high resolution analysis) or by fragile X-site determination -
1 or more identifications (OP) 106.05
Division 8 - Infertility and Pregnancy Tests
2370 Semen examination for presence of spermatozoa or examination of cervical mucus
for spermatozoa (Huhner's test) (SP) 9.30
2371 Semen examination for presence of spermatozoa or examination of cervical mucus
for spermatozoa (Huhner's test) (OP) 7.00
2372 Semen examination, involving measurement of volume, sperm count, motility, examination of stained preparations, morphology, and, if performed, differential count and 1 or more chemical tests, with a maximum of 4
examinations in any 12 month period (SP) 38.55
2373 Semen examination, involving measurement of volume, sperm count, motility, examination of stained preparations, morphology, and, if performed, differential count and 1 or more chemical tests, with a maximum of 4
examinations in any 12 month period (OP) 28.95
2377 Sperm antibodies, sperm penetrating
ability - 1 or more tests (SP) 24.80
2378 Sperm antibodies, sperm penetrating
ability - 1 or more tests (OP) 18.65
2379 Chorionic gonadotrophin (beta - HCG), qualitative estimation in serum or urine by 1 or more methods, including serial dilution if performed, for diagnosis of pregnancy - 1 or
more estimations (SP) 13.55
2380 Chorionic gonadotrophin (beta - HCG), qualitative estimation in serum or urine by 1 or more methods, including serial dilution if performed, for diagnosis of pregnancy - 1 or
more estimations (OP) 10.15
2384 Chorionic gonadotrophin (beta-HCG), qualitative (if performed) and quantitative estimation in serum by 1 or more methods for diagnosis of hydatidiform mole, HCG - secreting neoplasm, threatened abortion or
follow-up of abortion (SP) 38.55
2385 Chorionic gonadotrophin (beta-HCG), qualitative (if performed) and quantitative estimation in serum by 1 or more methods for diagnosis of hydatidiform mole, HCG - secreting neoplasm, threatened abortion or
follow-up of abortion (OP) 28.95

Division 9 - Simple Basic Pathology Tests
2387 Seminal examination for presence of
spermatozoa 6.20
2389 Blood count consisting of leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count) or any or all of haemoglobin estimation, haematocrit estimation or erythrocyte count - 1 procedure 4.15
2390 2 procedures specified in item 2389 6.20
2391 3 or more procedures specified in item 2389 8.25
2393 Microscopical examination of urine 4.15
2394 Pregnancy test by 1 or more immunochemical
methods 10.15
2395 Microscopical examination of wet film
other than urine 6.20
2396 Microscopical examination of gram-stained
film 7.85
2397 Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar
method 2.10
2398 Microscopical examination screening for fungi in skin, hair or nails - 1 or more
sites 6.20
2399 Mantoux test 10.15
ABBREVIATIONS
A. ABBREVIATIONS FOR GROUPS OF TESTS
Group Estimations
included in group Abbreviation Item
numbers
Cardiac Enzymes
Lactate dehydrogenase (LDH)
Aspartate aminotransferase (AST) and
Creatine kinase (CK) CE 1562, 1563
Coagulation Studies
Prothrombin Time, activated partial
thromboplastin time and 2 or more of the
following tests: bleeding time, thrombin
clotting time, fibrinogen degradation
products, fibrin monomer, D-dimer, Factor XIII
screening tests. COAG 1527, 1528
Electrolytes Sodium (NA),
Potassium (K),
Chloride (CL) and
Bicarbonate (HC03) E 1564, 1565
Lipid Studies Cholesterol (CHOL) and
Triglycerides (TRIG) FATS 1560, 1561
Liver Function Tests
Alkaline phosphatase (ALP),
Alanine aminotransferase
(ALT),
Aspartate aminotransferase
(AST)
Albumin (ALB), Bilirubin (BIL),
Gamma glutamyl
transpeptidase (GGT),
Lactate dehydrogenase (LDH)
and Protein (PROT) LFT 1571, 1572
Syphilis Serology
Rapid plasma reagin test
(RPR) or venereal disease
research laboratory
test (VDRL) and
Treponema pallidum
haemagglutin test (TPHA) or
Fluorescent Treponemal
antibody-absorption test
(FTA) STS 2183, 2184
B. ABBREVIATIONS FOR INDIVIDUAL TESTS
The abbreviations are listed alphabetically within the following Divisions:
1. HAEMATOLOGY
2. CHEMICAL PATHOLOGY
3. MICROBIOLOGY
4. IMMUNOLOGY
5. HISTOPATHOLOGY
6. CYTOPATHOLOGY
7. CYTOGENETICS
8. INFERTILITY AND PREGNANCY TESTS
Approved item name of test in Schedule
Abbreviation Item
numbers
DIVISION 1 - HAEMATOLOGY
Antithrombin III ATH 1531, 1532
Abnormal haemoglobins - spectroscopic
examination of blood AH 1419, 1420

Bleeding Time BT 1521, 1522
Blood coagulation factors - quantitative assays:
Von Willebrand's factor antigen VWA 1541, 1542
Von Willebrand's factor VWF 1541, 1542
Fletcher Factor FF 1541, 1542
Fitzgerald Factor FGF 1541, 1542
Passovy Factor PF 1541, 1542
Factor II FII 1541, 1542
Factor V FV 1541, 1542
Factor VII FVII 1541, 1542
Factor VIII FVIII 1541, 1542
Factor IX FIX 1541, 1542
Factor X FX 1541, 1542
Factor XI FXI 1541, 1542
Factor XII FXII 1541, 1542
Factor XIII XIII 1541, 1542
Blood Film BF 1170, 1171
Blood Group Antibodies BGA 1417, 1418
Blood Grouping - ABO and Rh (D antigen) BG 1187, 1188
Blood Group and blood group antibodies (group
and hold) BGAB 1196, 1197
Blood Group Systems (Duffy, Kell, M & N
factors, Rh phenotypes) BGS 1192, 1193
Bone Marrow Examination - Trephine BMET 1181, 1182
Bone Marrow Examination - Aspirate BMEA 1183, 1184
Carboxyhaemaglobin COHB 1419, 1420
Coagulation Time CT 1521, 1522
Cold Agglutinins CAG 1419, 1420
Compatibility testing XMAT 1198, 1199
C-reactive protein CRP 1163, 1164
Differential Cell Count DIFF 1170, 1171
Direct Coombs test CMBS 1419, 1420
D-dimer test DD 1521, 1522
Erythrocyte Count RCC 1163, 1164
Erythrocyte Metabolic Enzymes ERYM 1176, 1177
Erythrocyte Sedimentation Rate ESR 1163, 1164
Erythrocyte Haemolysis ERYH 1176, 1177
Euglobulin clot lysis time ECLT 1531, 1532
Fibrinogen Degradation Products FDP 1521, 1522
Fibrin Monomer FM 1521, 1522
Fibrinogen FIB 1521, 1522
Full Blood Examination FBE 1172, 1173
Haematocrit HCT 1163, 1164
Haemoglobin Estimation HB 1163, 1164
Haemoglobinopathy tests HMGP 1179, 1180
Heparin Cofactor II HRNC 1531, 1532
Heparin Estimation HEPR 1539, 1540
Heterophile Antibodies (Infectious
Mononucleosis Test) IM 1419, 1420
Leucocyte Count WCC 1163, 1164
Lupus Anticoagulant LUPA 1531, 1532
Metalbumin detection (Schumm's test) SCHM 1419, 1420
Plasminogen PLAS 1531, 1532
Partial Thromboplastin Time PTT 1521, 1522
Platelet Aggregation PLTG 1535, 1538
Platelet Count PLTC 1163, 1164
Protein C PROC 1531, 1532
Protein S PROS 1531, 1532
Prothrombin Time PT 1521, 1522
Red Cell Porphyrins - qualitative test RCP 1419, 1420
Reticulocyte Count RETC 1163, 1164
Test for Factor XIII Deficiency F13D 1521, 1522
Thalassaemia Studies TS 1179, 1180
Thrombin Time TT 1521, 1522
Viscosity of blood or plasma VISC 1163, 1164
DIVISION 2 - CHEMICAL PATHOLOGY
Acetoacetate ACAT 1791, 1792
Alanine Aminotransferase ALT 1558, 1559
Albumin ALB 1558, 1559
Alcohol (Ethanol) ETOH 1791, 1792
Alkaline Phosphatase ALP 1558, 1559
Alkaline Phosphatase Isoenzymes ALPI 1734, 1735
Aminoacids AMNA 1791, 1792
Amniotic Fluid Examination AFE 1726, 1727
Ammonia NH3 1791, 1792
Amylase AMS 1558, 1559
Angiotensin converting enzyme ACE 1791, 1792
Aspartate Aminotransferase AST 1558, 1559
Beta Hydroxybutyrate BHYB 1791, 1792
Bicarbonate HCO3 1558, 1559
Bilirubin (all Fractions) BILI 1558, 1559
Bilirubin (Neonatal) BILN 1791, 1792
Blood Gases GAS 1590, 1591
Breath Hydrogen Test BHT 1963, 1964
Calcium (total, dialysed or ionized) CA 1558, 1559
Calculus Analysis CALC 1595, 1596
Catecholamines CAT 1959, 1960
Cholinesterase CHSE 1791, 1792
Chloride CL 1558, 1559
Cholesterol CHOL 1558, 1559
Cystine (Cysteine) CYST 1791, 1792
Creatine Kinase CK 1558, 1559
Creatine Kinase Isoenzymes CKI 1558, 1559
Creatine Kinase Isoenzymes - Quantitative or Qualitative estimation by
electrophoresis CKIE 1734, 1735
Creatinine C 1558, 1559
Cryoglobulins CGLB 1575, 1576
Cryofibrinogen CFIB 1575, 1576
Drug or Chemical Assays - Overdose DRGO 1598, 1599
Drug Assays - Drug abuse treatment programme
including urinary drug screen DRGA 1627, 1628
Drug Assays - Therapeutic:
Antibiotics or antimicrobial chemotherapeutic agents (see under MICROBIOLOGY)
Acetylated Sulphadimidine ASUL 1712, 1713
Amiodarone AMIO 1712, 1713
Amitriptyline AMIT 1712, 1713
Amylobarb AMYL 1712, 1713
Barbitone BARB 1712, 1713
Bromide BRMD 1712, 1713
Butobarb BUTO 1712, 1713
Carbamazepine (Tegretol) CARB 1712, 1713
Chloral Hydrate CHHY 1712, 1713
Chlorazepate CHZP 1712, 1713
Chloropromazine CHLO 1712, 1713
Chloroquine CLOQ 1712, 1713
Cimetidine CMTD 1712, 1713
Clobozam CLOB 1712, 1713
Clonazepam (Rivotril) CLON 1712, 1713
Cylosporin A CLSA 1712, 1713
Desethyl Amiodarone DEAM 1712, 1713
Desipramine DESI 1712, 1713
Diazepam DIAZ 1712, 1713
Digoxin DIG 1712, 1713
Diphenylhydantoin (Dilantin) DIL 1712, 1713
Disopyramide (Rythmodan) DISO 1712, 1713
Doxepin DOXE 1712, 1713
Ethosuximide (Zarontin) ETHO 1712, 1713
Flecainide FLEC 1712, 1713
Hydroxychloriquine HOCQ 1712, 1713
Imipramine IMIP 1712, 1713
Lignocaine LIGN 1712, 1713
Methadone MTDN 1712, 1713
Methotrexate MTTA 1712, 1713
Methsuximide MSUX 1712, 1713
Metronidazole MRDZ 1712, 1713
Mexilitine (Mexitil) MEX 1712, 1713
N Acetyl Procainamide NAPC 1712, 1713
N Desalkyl Clobazan NDAC 1712, 1713
N Desalkyldothiepin NDOT 1712, 1713
N Desalkyl Doxepin NDAD 1712, 1713
Nitrazepam NITR 1712, 1713
Nordothiepin NDIP 1712, 1713
Nortriptyline NORT 1712, 1713
Oxazepam OXAZ 1712, 1713
Paracetamol PARA 1712, 1713
Paraquat PARQ 1712, 1713
Pentabarb PENT 1712, 1713
Perhexiline PHEX 1712, 1713
Phenobarbitone PHBA 1712, 1713
Phensoximide PHEN 1712, 1713
Phenytoin PHEY 1712, 1713
Prednisolone PRED 1712, 1713
Primidone PRIM 1712, 1713
Procainamide PCAM 1712, 1713
Prominal PROM 1712, 1713
Propanolol PPNO 1712, 1713
Quinalbarb QUIB 1712, 1713
Quinine QNN 1712, 1713
Quinidine QUIN 1712, 1713
Salicylate-Asprin SALI 1712, 1713
Sotalol SALL 1712, 1713
Stellazine STEL 1712, 1713
Sulphadimidine SPDD 1712, 1713
Sulthiame (Ospolot) SUL 1712, 1713
Theophylline THEO 1712, 1713
Thiopentone TOPO 1712, 1713
Thioridazine THIO 1712, 1713
Tocainide TOCN 1712, 1713
Trimipramine TRIM 1712, 1713
Valproate (Epilim) VALP 1712, 1713
Vancomycin VAN 1712, 1713
Warfarin WFR 1712, 1713
Therapeutic drugs that are not listed above must be written in full.
Electrophoresis
To demonstrate protein classes or presence
and amount of paraprotein classes EPP1 1734, 1735
To demonstrate protein classes or presence and amount of paraprotein classes - concurrent
collection EPP2 1736, 1737
Elements:
Aluminium AL 1871, 1872
Arsenic AS 1871, 1872
Beryllium BE 1871, 1872
Cadmium CD 1871, 1872
Chromium CR 1871, 1872
Copper CU 1871, 1872
Gold AU 1871, 1872
Lead PB 1895, 1896
Manganese MN 1871, 1872
Mercury HG 1871, 1872
Nickel NI 1871, 1872
Selenium SE 1871, 1872
Strontium SR 1871, 1872
Zinc ZN 1791, 1792 Enzyme assays of solid tissue or
tissues ENZS 1969, 1970
Faecal Fat FFAT 1963, 1964
Faecal Haemoglobin (chemical test) FHC 1577, 1578
Faecal Haemoglobin (immunological test) FHI 1579, 1580
Faecal Porphyrins (qualitative test) FPR 1577, 1578
Faecal Reducing Substances FRS 1577, 1578
Fructosamine FRUC 1558, 1559
Gamma Glutamyl Transpeptidase GGT 1558, 1559
Globulin GLOB 1558, 1559
Glucose GLUC 1558, 1559
Glucose Tolerance Test GTT 1558, 1559
Glycosylated Haemoglobin (Hb Alc) GHB 2043, 2044
HDL Cholesterol HDLC 2039, 2040
Hormones:

Adrenocorticotrophic hormone ACTH 2021, 2024
Aldosterone ALDS 2021, 2024
Androstenedione ANDR 2021, 2024
Arginine ARIN 1991, 1992
C-Peptide CPEP 2021, 2024
Calcitonin CALT 2021, 2024
Cortisol CORT 2021, 2024
Cyclic AMP CAMP 2021, 2024
Dehydroepiandrosterone sulphate DHEA 2021, 2024
Dexamethasone DXST 1989, 1990
Dexamethazone Suppression test DEXA 2021, 2024
Dihydrotestosterone DHTS 2021, 2024
Follicular Stimulating Hormone FSH 2021, 2024
Gastrin GAST 2021, 2024
Glucagon GLGO 2021, 2024
Glucagon - stimulation test GSTC 1991, 1992
Gonadotrophin GRHS 1991, 1992
Growth Hormone GH 2021, 2024
Growth Hormone - exercise GHSE 1989, 1990
Growth Hormone - glucose GHSG 1989, 1990
Hormone Receptor Assay HRA 2037, 2038
Human Placental Lactogen HPL 2021, 2024
Hydroxyprogesterone OHP 2021, 2024
Insulin INS 2021, 2024
Insulin - stimulation test INHY 1991, 1992
L-Dopa GHLD 1989, 1990
Luteinizing Hormone LH 2021, 2024
Oestradiol E2 2021, 2024
Oestriol E3 2021, 2024
Oestrone E1 2021, 2024
Parathyroid Hormone PTH 2021, 2024
Pentagastrin PSTR 1991, 1992
Progesterone PROG 2021, 2024
Prolactin PROL 2021, 2024
Renin REN 2021, 2024
Secretin SSGR 1991, 1992
Sex Hormone Binding Globulin SHBG 2021, 2024
Somatomedin SOMA 2021, 2024
Testosterone TES 2021, 2024
Thyroid Stimulating Hormone TSH 2021, 2024
Urine Steroid Fraction or Fractions USF 2021, 2024
Vasoactive Intestinal Peptide VIP 2021, 2024
Vasopressin ADH 2021, 2024
11 Deoxycortisol DCOR 2021, 2024
HIAA (Hydroxyindoleacetic acid) HIAA 1791, 1792
Histamine HIAM 1791, 1792
HMMA (Hydroxy Methoxy Mandelic acid previously
known as VMA) HMMA 1959, 1960
HVA (Homovanillic acid) HVA 1959, 1960
Hydroxyproline HYDP 1791, 1792
Intestinal disaccharidases INTD 1969, 1970
Iron Studies (Iron, Transferrin and Ferritin) IS 1752, 1753
Lactate LACT 1791, 1792
Lactate Dehydrogenase LDH 1558, 1559
Lactate Dehydrogenase Isoenzymes LDI 1734, 1735
Lamellar Body Phospholipid LBPH 1726, 1727
Lecithin/Sphingomyelin Ratio (Amniotic fluid) LS 1726, 1727
Lipase LIP 1558, 1559
Lithium LI 1558, 1559
Magnesium MG 1558, 1559
Metanephrines MNEP 1959, 1960
MHPG (Methoxy Hydroxy Phenyethylene Glycol) MHPG 1959, 1960
Osmolality, Serum or Urine OSML 1583, 1584
Oxalate OXAL 1791, 1792
PAA (Phenyl Acetic Acid) PAA 1959, 1960
Palmitic acid in amniotic fluid PALM 1726, 1727
pH measurement of body fluids other than
urine PH 1575, 1576
Phosphate PHOS 1558, 1559
Phosphatidylglycerol PTGL 1726, 1727
Porphyrins (quantitative test, one or more
fractions) PR 1959, 1960
Potassium K 1558, 1559
Prealbumin PALB 1738, 1739
Protein (Total) PROT 1558, 1559
Protein - Quantitative Estim. of Specific Protein:
Alpha feto protein AFP 1738, 1739
Alpha - 1 antitrypsin AAT 1738, 1739
Alpha - 2 macroglobulin AMAC 1738, 1739
Beta-2 microglobulin BMIC 1738, 1739
C-1 esterase inhibitor CEI 1738, 1739
Caeruloplasmin CPLS 1738, 1739
Ferritin FERR 1738, 1739
Haptoglobins HGLB 1738, 1739
Microalbumin MALB 1738, 1739
Transferrin TRAN 1738, 1739
Pyruvate PVTE 1791, 1792
Red Cell Folate and Serum B12 and, if
required, Serum Folate RCF 1770, 1771
Serotonin 5HT 1791, 1792
Serum B12 B12 1768, 1769
Serum Folate FOL 1768, 1769
Snake Venom HISS 1598, 1599
Sodium NA 1558, 1559
Synacthen Stimulation Test SYNS 2021, 2024
Thyroid Function Tests TFT 1983, 1984
Thyroid Stimulating Hormone (where not
requested as part of a TFT) TSH 2021, 2024
Thyrotrophin Releasing Hormone Test TRH 1985, 1986
Total Free Fatty Acids TFFA 1791, 1792
Triglycerides TRIG 1558, 1559
Tumour Markers:
CA-125 antigen C125 1738, 1739
CA-19.9 antigen CA19 1738, 1739
CA-15.3 antigen CA15 1738, 1739
Carcinoembryonic antigen CEA 1738, 1739
Mammary Serum antigen MSA 1738, 1739
Mucin-like carcinoma associated antigen MCA 1738, 1739
Neuron specific enolase NSEN 1738, 1739
Prostate specific antigen PSA 1738, 1739
Prostatic acid phosphotase - one or more
fractions ACP 1738, 1739
SCC related antigen SCCA 1738, 1739
Thyroglobulin TGL 1738, 1739 Thyrotrophin Releasing Hormone Test TRH 1985, 1986
Urate URAT 1558, 1559
Urea U 1558, 1559
Urine Bilirubin UBIL 1575, 1576
Urine Cystine (Cysteine) UCYS 1575, 1576
Urine Haemoglobin UHB 1575, 1576
Urine Melanin (Melanogen) UML 1575, 1576
Urine Myoglobin UMY 1575, 1576
Urine Porphobilinogen UPG 1575, 1576
Urine Porphyrins (qualitative test) UPR 1575, 1576
Urine Urobilinogen UUB 1575, 1576
Vitamin D VITD 1786, 1787
Vitamin, Quantitative Estimation of Vitamins
A, B1, B2, B3, B6, C or E VIT 1780, 1783
Xylose XYL 1791, 1792
DIVISION 3 - MICROBIOLOGY
Antibiotic and antimicrobial chemotherapeutic
agents, quantitative assay QAA 2235, 2236
Blood Culture BC 2123, 2124
Chlamydia Investigation by Cultural Methods CHLC 2139, 2140
Clostridium difficile CLDT 2129, 2130
CSF antigens - Haemophilus influenzae, Streptococcus pneumoniae,
Neisseria menigitidis, Group B Streptococcus CSFA 2129, 2130
Cryptococcal antigen CRYN 2129, 2130
Cultural Examination of faeces FCS 2117, 2118
Hepatitis Serology:
Hepatitis Serology in Acute Hepatitis HEP 2229, 2230
Hepatitis B Serology in follow up of proven
Hepatitis B HEPB 2231, 2232
Hepatitis B Surface antigen HBsAg HBSA 2221, 2222
Hepatitis B Serology to define immune status HEPI 2223, 2224
Herpes simplex Virus Investigation by Cultural
Methods HSVC 2139, 2140
Microbial Antibody Testing:
(IgG, IgM, IgA or Total antibodies may be tested against various organisms and are indicated by placing the letter G, M, A and T respectively on the end of the 3 letter abbreviation)
Actinomycetes ACT 2181, 2182
Adenovirus ADE 2181, 2182
Aspergillus ASP 2181, 2182
Avian precipitins (Bird Fancier's Disease) APP 2181, 2182
Blastomyces BLM 2181, 2182
Bordetella pertussis BOR 2181, 2182
Borrelia Berghoffer BOB 2181, 2182
Brucella BRU 2181, 2182
Campylobacter jejuni CAM 2181, 2182
Candida CAN 2181, 2182
Chlamydia CHL 2181, 2182
Coccidioides CCC 2181, 2182
Coxsackie B1-6 COX 2181, 2182
Cryptococcus CRY 2181, 2182
Cytomegalovirus CMV 2181, 2182
Cytomegalovirus Serology in Pregnancy CMVP 2145, 2146
Dengue DEN 2181, 2182
Diphtheria DIP 2181, 2182
Echinococcus ECC 2181, 2182
Echo-coxsackie group ECH 2181, 2182
Entamoeba histolytica AMO 2181, 2182
Epstein Barr Virus EBV 2181, 2182
Fluorescent Treponemal antibody - absorption
test (FTA-ABS) FTA 2181, 2182
Haemophilus HUS 2181, 2182
Hepatitis delta antibody - Anti-delta HDA 2181, 2182
Histoplasma HIP 2181, 2182
Hydatid HYD 2181, 2182
Influenza A FLA 2181, 2182
Influenza B FLB 2181, 2182
Legionella pneumophila - Serogroup 1 LP1 2181, 2182
Legionella pneumophila - Serogroup 2 LP2 2181, 2182
Leishmaniasis LEI 2181, 2182
Leptospira LEP 2181, 2182
Listeria LIS 2181, 2182
Measles MEA 2181, 2182
Micropolyspora faeni MIC 2181, 2182
Mumps MUM 2181, 2182
Murray Valley Encephalitis MVE 2181, 2182
Mycoplasma pneumoniae MYC 2181, 2182
Neisseria gonorrhoea GON 2181, 2182
Newcastle Disease NCD 2181, 2182
Parainfluenza 1 PF1 2181, 2182
Parainfluenza 2 PF2 2181, 2182
Parainfluenza 3 PF3 2181, 2182
Paratyphi PTY 2181, 2182
Pertussis PER 2181, 2182
Pneumococcus PCC 2181, 2182
Poliomyelitis PLO 2181, 2182
Proteus OX 19 POX 2181, 2182
Proteus OXK POK 2181, 2182
Q fever QFF 2181, 2182
Rapid Plasma Reagin test RPR 2181, 2182
Respiratory Syncytial Virus RSV 2181, 2182
Ross River Virus RRV 2181, 2182
Rubella RUB 2181, 2182
Rubella Serology in Pregnancy RUBP 2145, 2146
Salmonella typhi (H) SAH 2181, 2182
Salmonella typhi (O) SAO 2181, 2182
Schistosoma STO 2181, 2182
Streptococcal Serology--Anti-D-Nase B titre ADNB 2181, 2182
Streptococcal Serology--Anti-streptolysin O
titre ASOT 2181, 2182
Tetanus TET 2181, 2182
Thermoactinomyces vulgaris THE 2181, 2182
Thermopolyspora TPS 2181, 2182
Toxocara TOC 2181, 2182
Toxoplasma TOX 2181, 2182
Toxoplasma Serology in Pregnancy TOXP 2145, 2146
Treponema pallidum haemagglutin test TPHA 2181, 2182
Trichonosis TOS 2181, 2182
Typhus, Weil-Felix TYP 2181, 2182
Varicella zoster VCZ 2181, 2182
Venereal Disease Research Laboratory (VDRL) VDRL 2181, 2182
Yersinia enterocolytica YER 2181, 2182
Microbial antibody tests which are not listed above must be written in full.
Microbial Antigen Testing:
Chlamydia CHLY 2133, 2134
Herpes simplex Virus HSV 2135, 2136
Microscopic examination of faeces for
parasites OCP 2085, 2086
Microscopic examination of material other than
blood M 2083, 2084
Microscopy and culture of material from nose,
throat, eye and ear MCS1 2087, 2088
Microscopy and culture of material from skin, superficial sites, urethra, vagina, cervix,
sputum or rectum MCS2 2089, 2090
Microscopy and culture of material from post operative wounds, aspirations of body cavities, synovial fluid, CSF and operative or
biopsy specimens MCS3 2098, 2099
Microscopy and culture of sputum for
mycobacteria AFB 2119, 2120
Respiratory Syncytial Virus RSVN 2129, 2130
Urine microscopy, culture, identification and
sensitivity UMCS 2127, 2128
Varicella zoster VCZN 2129, 2130
DIVISION 4 - IMMUNOLOGY
Specific IgG or IgE antibodies ALLG 2259, 2260
Antibodies to Tissue Antigens:
Acetylcholine receptor ARA 2271, 2274
Adrenal cell ADR 2271, 2274

Cardiolipin ACL 2271, 2274
Centromere ACA 2271, 2274
Gliadin IgA GLIA 2271, 2274
Gastric parietal cell PCA 2271, 2274
Glomerular basement membrane GBA 2271, 2274
Insulin Receptor Antibodies INSA 2271, 2274
Intercellular Cement Substance of Skin ICCS 2271, 2274
Jo-1 JO1 2271, 2274
Keratin KERA 2271, 2274
Liver/Kidney microsomes LKA 2271, 2274
Mitochondria MA 2271, 2274
Parathyroid cell PTHA 2271, 2274
PM-1 PM1 2271, 2274
Reticulin RCA 2271, 2274
SCL 70 SCL 2271, 2274
Skeletal muscle SLA 2271, 2274
Skin basement membrane SKA 2271, 2274
Smooth muscle SMA 2271, 2274
Thyroid microsomal TMA 2271, 2274
TSH Receptor Antibody test TSHA 2271, 2274
Tissue antigens which are not listed above must be written in full
Antibodies to Nuclear Antigens - detection ANA 2261, 2262
Antibodies to Nuclear Antigens - quantitation and Measurement of DNA Binding if Positive
ANA ANAP 2263, 2266
Antibodies to Extractable Nuclear Antigens -
detection ENA 2267, 2268
Antibodies to Extractable Nuclear Antigens -
characterization of antibodies if positive
ENA ENAP 2269, 2270
Complement Total, C3 or C4
Other complements must be specified COM 2289, 2290
HLA Typing, comprising A, B, C and DR
Phenotypes HLA 2321, 2322
HLA Typing, 1 or more antigens HLAN 2323, 2324
Immunoglobulins G, A, M or D IG 2245, 2246
Immunoglobulin G, Subclasses 1-4 SIGG 2255, 2256
Immunoglobulin E IGE 2257, 2258
Leucocyte Fractionation LF 2313, 2314
Leucocyte Functional Tests LFF 2315, 2316
Leucocyte Surface Markers to assess lymphoid
populations LSML 2317, 2318
Leucocyte Surface Markers in investigation of
probable haematological malignancy LSMH 2319, 2320
Mantoux Test MANT 2325, 2326
Paraprotein Investigation by Immuno-electrophoreses
or immunofixation PPRO 2239, 2240
Paraprotein Investigation on Concurrently
Collected Serum and Urine PPSU 2241, 2242
Rheumatoid Factor (all tests including Latex
test) RF 2281, 2282
Rheumatoid Factor quantitation RFQ 2283, 2284

DIVISION 5 - HISTOPATHOLOGY
Electron microscopy of biopsy material EM 2333, 2337
Histopathology of biopsy material HIST 2327, 2328
Immediate frozen section diagnosis of biopsy
material FS 2329, 2330
Immunohistochemical investigation of biopsy
material IHIS 2331, 2332
DIVISION 6 - CYTOPATHOLOGY
Cytology from cervix or vagina CXCY 2338, 2339
Cytology from skin, nipple discharge, lip,
mouth, nose or anus SMCY 2340, 2341
Cytology from body fluids, sputum (1
specimen), washings or brushings BFCY 2340, 2341
Cytology from 3 sputum or urine specimens SPCY 2348, 2349
Cytology from fine needle aspiration of solid
tissues FNCY 2350, 2351
Cytology from fine needle aspiration of solid tissues - aspiration or attendance by
Pathologist FNCP 2355, 2356
DIVISION 7 - CYTOGENETICS
Chromosome studies CS 2360, 2361
Chromosome studies of blood CSB 2363, 2364
Chromosome identification by banding
techniques CSI 2365, 2366
DIVISION 8 - INFERTILITY AND PREGNANCY TESTS
Semen examination for spermatozoa SES 2370, 2371
Huhner's test HT 2370, 2371
Semen examination SEE 2372, 2373
Sperm antibodies SAB 2377, 2378
Sperm penetrating ability SPA 2377, 2378
Chorionic gonadotrophin for pregnancy
diagnosis HCG 2379, 2380
Chorionic gonadotrophin for diagnosis of
specified conditions HCGD 2384, 2385